Chemomab Therapeutics Ltd. (CMMB) Balance Sheet
CMMB balance sheet, 2025
December 31, 2025 · U.S. dollars$13.8M assets = $1.5M liabilities + $12.3M equity
Both columns are drawn to the same scale: what CMMB owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CMMB financial health
Descriptive bands, not a rating. Fiscal 2025.
CMMB balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $5.6M2016 | $13.8M2025 | +10.4%/yr | |
| Total liabilities | $2.4M2016 | $1.5M2025 | −5.1%/yr | |
| Shareholders’ equity | $3.3M2016 | $12.3M2025 | +15.8%/yr | |
| Cash & short-term investments | $4.6M2016 | $10.4M2025 | +9.6%/yr | |
| Total debt | $586,0002019 | $324,0002024 | −11.2%/yr | |
| Net cash (debt) | $17.0M2019 | $13.9M2024 | −$3.0M | |
| Working capital | $2.5M2016 | $11.9M2025 | +$9.4M | |
| Book value per share | $23.702021 | $1.932025 | −46.6%/yr | |
| Current ratio | 2.072016 | 9.082025 | +7.02 | |
| Debt / equity | 0.052019 | 0.022024 | −0.02 | |
| Shares outstanding | 2.6M2021 | 6.4M2025 | +25.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CMMB assets
CMMB liabilities and equity
CMMB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CMMB balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $10.4M | $14.3M | $19.8M | $39.9M | $61.2M | $11.7M | $17.6M | $7.5M | $1.5M | $4.6M |
| Cash & equivalents | $7.6M | $6.1M | $9.3M | $13.5M | $15.2M | $11.7M | $17.6M | $7.5M | $1.5M | $4.6M |
| Short-term investments | $2.8M | $8.2M | $10.5M | $26.4M | $46.0M | $24,000 | — | — | — | — |
| Receivables | $3.1M | $263,000 | $289,000 | $459,000 | $179,000 | $74,000 | $636,000 | $3.4M | $88,000 | $139,009 |
| Inventory | $0 | $1 | −$1.0M | $0 | −$1.3M | −$657,000 | −$542 | −$77,000 | $0 | $1 |
| Other current assets | $0 | $1.5M | $1.9M | $1.4M | $2.7M | $724,000 | $543 | $77,000 | $47,000 | $169,150 |
| Total current assets | $13.4M | $16.0M | $20.9M | $41.7M | $62.7M | $11.8M | $18.2M | $10.9M | $1.6M | $4.9M |
| Property, plant & equipment (net) | $175,997 | $525,000 | $686,980 | $580,000 | $688,000 | $580,000 | $1.4M | $385,000 | $219,000 | $213,321 |
| Goodwill & intangible assets | $14,000 | $14,000 | $8,020 | $14,000 | $14,000 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $4,000 | $0 | $0 | $0 | $0 |
| Other non-current assets | $196,997 | $385,000 | $559,000 | $733,000 | $963,000 | $53,000 | $187,004 | $1.5M | $279,000 | $567,732 |
| Total assets | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M | $12.5M | $19.8M | $12.8M | $2.1M | $5.6M |
| Liabilities | ||||||||||
| Accounts payable | $484,992 | $633,000 | $516,000 | $1.7M | $1.3M | $93,000 | $25,000 | $395,996 | $160,001 | $106,530 |
| Short-term debt | — | $115,000 | $76,000 | $123,000 | $106,000 | $249,000 | $478,000 | — | — | — |
| Deferred revenue | — | — | — | — | — | — | $2 | — | — | — |
| Total current liabilities | $1.5M | $3.2M | $4.8M | $6.7M | $2.6M | $1.3M | $4.1M | $2.7M | $2.7M | $2.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $0 | $324,000 | $392,000 | $214,000 | $343,000 | $195,000 | $1.1M | — | — | — |
| Other long-term liabilities | $0 | $209,000 | $316,000 | $91,000 | $237,000 | $358,000 | $725,000 | $210,000 | $0 | $0 |
| Total liabilities | $1.5M | $3.4M | $5.2M | $6.8M | $2.9M | $1.7M | $4.8M | $3.0M | $2.7M | $2.4M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | — | — | — | — | — | — | — | — | $2.8M | $1.9M |
| Retained earnings (deficit) | −$111.6M | −$102.6M | −$88.7M | −$63.8M | −$36.2M | −$23.7M | −$17.7M | −$78.3M | −$62.9M | −$52.7M |
| Accumulated other comprehensive income | — | $0 | — | $0 | $0 | $872,000 | $872,000 | $4.4M | $2.2M | $1.3M |
| Total shareholders' equity | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M | $10.8M | $12.4M | $9.8M | −$609,000 | $3.3M |
| Key figures | ||||||||||
| Total debt | — | $324,000 | $392,000 | $214,000 | $343,000 | $607,000 | $586,000 | — | — | — |
| Net cash (debt) | — | $13.9M | $19.4M | $39.7M | $60.8M | $11.1M | $17.0M | — | — | — |
| Working capital | $11.9M | $12.8M | $16.1M | $35.0M | $60.0M | $10.5M | $14.1M | $8.2M | −$1.1M | $2.5M |
| Tangible book value | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M | $10.8M | $12.4M | $9.8M | −$609,000 | $3.3M |
| Book value per share | $1.93 | — | $5.79 | $12.73 | $23.70 | — | — | — | — | — |
| Shares outstanding | 6.4M | — | 2.9M | 2.8M | 2.6M | — | — | — | — | — |
| Current ratio | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 | 9.00 | 4.42 | 3.98 | 0.59 | 2.07 |
| Quick ratio | 9.08 | 4.51 | 4.15 | 5.98 | 23.15 | 8.95 | 4.42 | 3.98 | 0.57 | 1.99 |
| Debt / equity | — | 0.02 | 0.02 | 0.01 | 0.01 | 0.06 | 0.05 | — | — | — |
| Equity / assets | 89.3% | 79.8% | 76.7% | 84.1% | 95.5% | 86.6% | 62.6% | 76.8% | −29.2% | 58.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $6.7M | $8.0M | $10.4M | $10.1M | $9.4M | $10.6M | $14.3M | $19.4M | $12.7M | $15.9M | $19.8M | $21.4M |
| Cash & equivalents | $6.0M | $5.9M | $7.6M | $7.0M | $5.4M | $8.3M | $6.1M | $6.6M | $5.0M | $4.7M | $9.3M | $9.2M |
| Short-term investments | $687,995 | $2.1M | $2.8M | $3.1M | $3.9M | $2.2M | $8.2M | $12.8M | $7.7M | $11.2M | $10.5M | $12.2M |
| Receivables | $3.3M | $3.4M | $3.1M | $1.7M | $1.1M | $1.3M | $0 | $439,000 | $654,000 | $885,000 | $289,000 | $921,985 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1 | $0 | $0 | −$654,000 | −$885,000 | −$1.0M | −$993 |
| Other current assets | $1 | $0 | $0 | $149,000 | $148,000 | $139,999 | $1.8M | $75,000 | $728,000 | $960,000 | $1.9M | $994 |
| Total current assets | $10.0M | $11.5M | $13.4M | $11.9M | $10.6M | $12.0M | $16.0M | $19.9M | $13.5M | $16.8M | $20.9M | $22.4M |
| Property, plant & equipment (net) | $157,998 | $167,000 | $175,997 | $188,000 | $217,000 | $501,000 | $539,000 | $577,000 | $617,000 | $656,000 | $686,980 | $448,993 |
| Goodwill & intangible assets | $0 | $0 | $14,000 | $0 | $0 | $14,000 | $6,620 | $0 | $0 | $0 | $8,020 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $123,000 | $167,004 | $196,997 | $254,000 | $298,000 | $327,000 | $378,380 | $428,000 | $472,000 | $516,000 | $559,000 | $602,991 |
| Total assets | $10.2M | $11.8M | $13.8M | $12.4M | $11.1M | $12.8M | $17.0M | $20.9M | $14.5M | $18.0M | $22.2M | $23.4M |
| Liabilities | ||||||||||||
| Accounts payable | $256,998 | $204,000 | $484,992 | $194,000 | $378,000 | $490,000 | $666,000 | $386,000 | $1.1M | $527,000 | $516,000 | $730,988 |
| Short-term debt | — | — | — | — | — | $113,000 | $115,000 | $112,000 | $109,000 | $110,000 | $76,000 | $105,000 |
| Deferred revenue | — | — | — | — | — | — | — | — | $1 | $1 | — | $1 |
| Total current liabilities | $1.6M | $1.1M | $1.5M | $1.1M | $1.4M | $2.2M | $3.2M | $4.3M | $4.3M | $4.4M | $4.8M | $5.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | $0 | $0 | $0 | $292,000 | $324,000 | $342,000 | $360,000 | $390,000 | $392,000 | — |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $179,000 | $209,000 | $230,000 | $251,000 | $280,000 | $316,000 | $5,000 |
| Total liabilities | $1.6M | $1.1M | $1.5M | $1.1M | $1.4M | $2.4M | $3.4M | $4.6M | $4.6M | $4.7M | $5.2M | $5.4M |
| Shareholders' equity | ||||||||||||
| Retained earnings (deficit) | −$115.6M | −$113.4M | −$111.6M | −$109.7M | −$108.0M | −$105.9M | −$102.6M | −$99.7M | −$96.2M | −$92.5M | −$88.7M | −$84.6M |
| Accumulated other comprehensive income | — | — | — | — | — | $0 | $0 | — | — | $0 | — | $0 |
| Total shareholders' equity | $8.7M | $10.7M | $12.3M | $11.2M | $9.7M | $10.4M | $13.5M | $16.3M | $10.0M | $13.3M | $17.0M | $18.0M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | $292,000 | $324,000 | $342,000 | $360,000 | $390,000 | $392,000 | $109,998 |
| Net cash (debt) | — | — | — | — | — | $10.3M | $13.9M | $19.0M | $12.4M | $15.5M | $19.4M | $21.3M |
| Working capital | $8.4M | $10.4M | $11.9M | $10.8M | $9.2M | $9.7M | $12.8M | $15.5M | $9.1M | $12.4M | $16.1M | $17.0M |
| Tangible book value | $8.7M | $10.7M | $12.3M | $11.2M | $9.7M | $10.4M | $13.5M | $16.3M | $10.0M | $13.3M | $17.0M | $18.0M |
| Book value per share | $1.09 | $1.34 | $1.58 | $1.82 | $1.67 | $1.82 | $0.72 | $3.72 | — | — | — | — |
| Shares outstanding | 8.0M | 8.0M | 7.8M | 6.2M | 5.8M | 5.7M | 18.9M | 4.4M | — | — | — | — |
| Current ratio | 6.41 | 10.31 | 9.08 | 10.49 | 7.42 | 5.33 | 4.98 | 4.57 | 3.12 | 3.83 | 4.32 | 4.16 |
| Quick ratio | 6.41 | 10.31 | 9.08 | 10.36 | 7.32 | 5.27 | 4.43 | 4.56 | 3.11 | 3.81 | 4.15 | 4.16 |
| Debt / equity | — | — | — | — | — | 0.03 | 0.02 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 |
| Equity / assets | 84.8% | 90.6% | 89.3% | 90.8% | 87.2% | 81.1% | 79.8% | 78.1% | 68.7% | 74.0% | 76.7% | 77.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 23, 2026); data from EODHD.
CMMB financial position
At the end of fiscal 2025 (December 31, 2025), Chemomab Therapeutics had total assets of $13.8 million (down 18.6% from a year earlier), total liabilities of $1.5 million and shareholders' equity of $12.3 million. Its current ratio was 9.08. In the latest quarter (ended June 30, 2026) total assets were $10.2 million and equity $8.7 million.
Related: CMMB income statement, CMMB cash flow statement, CMMB key metrics. See the CMMB stock overview for the latest quote and news.
CMMB balance sheet FAQ
What are Chemomab Therapeutics's total assets?
Chemomab Therapeutics reported total assets of $13.8 million at the end of fiscal 2025 (December 31, 2025), compared with $17.0 million a year earlier.
How much cash does Chemomab Therapeutics have?
Chemomab Therapeutics held $10.4 million in cash and short-term investments at the end of fiscal 2025.
What is Chemomab Therapeutics's book value?
Chemomab Therapeutics's shareholders' equity (book value) was $12.3 million at the end of fiscal 2025, or $1.93 per share.
What is Chemomab Therapeutics's current ratio?
Chemomab Therapeutics had current assets of $13.4 million and current liabilities of $1.5 million, a current ratio of 9.08 (it can cover its short-term obligations).
How much goodwill does Chemomab Therapeutics have?
Chemomab Therapeutics carried $0.0 million of goodwill and intangible assets, 0.1% of total assets, at the end of fiscal 2025.